Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded at StockNews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

Brainstorm Cell Therapeutics Price Performance

Shares of NASDAQ BCLI opened at $1.99 on Wednesday. The company has a market capitalization of $11.35 million, a price-to-earnings ratio of -0.41 and a beta of 0.29. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.89. The business has a 50-day moving average of $1.92 and a 200-day moving average of $2.97.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.